Mablink Bioscience appoints Dr. Lenka Kyrych Sadilkova as its Head of Preclinical Research and Development to support the development of its pipeline of ADC candidates using its proprietary PSARlink™ linker

Lyon, France, March 15, 2022

Mablink Bioscience S.A.S. (“Mablink”), a biotechnology company developing a pipeline of antibody-drug conjugates (ADCs) based on its proprietary PSARlink™ drug-linker technology to treat cancers with high unmet needs, today announced the appointment of its Head of Preclinical Research and Development: Dr. Lenka Kyrych Sadilkova, PhD.

She held several positions in the field of bioconjugation and recombinant proteins with several academic institutions. She has worked for 6 years at the Czech Academy of Sciences and for 4 years as a Scientific Lead in the laboratory of clinical pharmacology in one of the Czech largest hospitals. During the years, her work was focused on engineering of recombinant proteins, vaccination strategies and vaccine development and research projects related to pharmacokinetic and pharmacodynamic modeling of selected standard of care regimens in geriatric patients with translational overlaps. Dr. Kyrych Sadilkova brings her skills in non-clinical pharmacology and team management that she has gained during her 9 years at SOTIO Biotech a.s., a Czech biotech company focusing on the development of innovative oncology immunotherapies. After several years as a Pharmacology Lead, she was promoted to the position of Director of Pharmacology responsible for non-clinical development of several antibody-drug conjugates, with the first one currently successfully entering in Phase 1.

An expert in ADCs, she will lead Mablink’s biology laboratory, in close collaboration with the CSO and the CDO, to support the development of MBK-103, Mablink’s lead ADC candidate. With her specific experience in target validation and antibody development, she will be instrumental in helping Mablink evolve from being a drug-linker company to becoming an ADC developer with an exciting pipeline of new ADC candidates.

Dr. Kyrych Sadilkova holds a PhD in Biochemistry and Molecular Biology and a PhD in Gerontology, both from Charles University (Prague, Czech Republic).

Read more >